Sun Pharmaceutical Industries Limited (BOM:524715)
India flag India · Delayed Price · Currency is INR
1,845.20
-45.95 (-2.43%)
At close: May 22, 2026

BOM:524715 Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Revenue
582,201525,784484,969438,857386,545
Other Revenue
22,137----
604,338525,784484,969438,857386,545
Revenue Growth (YoY)
14.94%8.42%10.51%13.53%15.39%
Cost of Revenue
115,437115,585114,422113,187108,761
Gross Profit
488,901410,200370,547325,670277,784
Selling, General & Admin
114,189100,50995,02583,54973,544
Other Operating Expenses
190,083157,883144,755123,779101,331
Operating Expenses
333,650284,145265,345232,613196,223
Operating Income
155,251126,055105,20293,05881,560
Interest Expense
-3,389-2,314-2,385-1,720-1,274
Interest & Investment Income
-12,97011,2625,3107,687
Earnings From Equity Investments
-558.7-153.5-384.1-479-165.4
Currency Exchange Gain (Loss)
12,4021,855361.3-1,2611,540
Other Non Operating Income (Expenses)
-620.6546.7756.5735.9
EBT Excluding Unusual Items
163,705139,034114,60395,66490,084
Merger & Restructuring Charges
--3,617-739.5-643.9-563.5
Gain (Loss) on Sale of Investments
-5,117921.9-240.37.7
Gain (Loss) on Sale of Assets
--164-99.775.4347.5
Asset Writedown
--71.3-1,564-312.5-2,179
Legal Settlements
--58.2---1,563
Other Unusual Items
-13,075-3,104-2,712-1,071-41,657
Pretax Income
150,630137,368110,49593,60544,648
Income Tax Expense
35,54427,72014,3958,47610,755
Earnings From Continuing Operations
115,087109,64896,10085,12933,893
Minority Interest in Earnings
-292.3-357.1-336.5-393.6-1,166
Net Income
114,794109,29095,76484,73632,727
Net Income to Common
114,794109,29095,76484,73632,727
Net Income Growth
5.04%14.12%13.01%158.92%12.70%
Shares Outstanding (Basic)
2,4022,3992,3992,3992,399
Shares Outstanding (Diluted)
2,4022,3992,3992,3992,399
Shares Change (YoY)
0.09%----
EPS (Basic)
47.8045.5539.9135.3213.64
EPS (Diluted)
47.8045.5539.9035.3013.60
EPS Growth
4.94%14.16%13.03%159.56%12.40%
Free Cash Flow
88,098119,43599,33228,73874,895
Free Cash Flow Per Share
36.6849.7841.4011.9831.21
Dividend Per Share
-16.00013.50011.50010.000
Dividend Growth
-18.52%17.39%15.00%33.33%
Gross Margin
80.90%78.02%76.41%74.21%71.86%
Operating Margin
25.69%23.97%21.69%21.20%21.10%
Profit Margin
19.00%20.79%19.75%19.31%8.47%
Free Cash Flow Margin
14.58%22.72%20.48%6.55%19.38%
EBITDA
184,629149,679128,760116,513101,536
EBITDA Margin
30.55%28.47%26.55%26.55%26.27%
D&A For EBITDA
29,37923,62523,55923,45619,975
EBIT
155,251126,055105,20293,05881,560
EBIT Margin
25.69%23.97%21.69%21.20%21.10%
Effective Tax Rate
23.60%20.18%13.03%9.05%24.09%
Revenue as Reported
604,338545,435498,510445,202395,760
Source: S&P Global Market Intelligence. Standard template. Financial Sources.